← All stories
Markets
STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
The FDA has rejected a radiopharmaceutical therapy due to manufacturing issues, halting what would have been a competitor for Novartis.
Covered by 1 outlet
All coverage · 1 article